

UCSF

UC San Francisco Previously Published Works

Title

In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes

Permalink

<https://escholarship.org/uc/item/00h6x5hm>

Journal

Nature, 485(7400)

ISSN

0028-0836

Authors

Qian, Li
Huang, Yu
Spencer, C Ian
[et al.](#)

Publication Date

2012-05-01

DOI

10.1038/nature11044

Peer reviewed



HHS Public Access

Author manuscript

Nature. Author manuscript; available in PMC 2012 November 30.

Published in final edited form as:

Nature. 2012 May 31; 485(7400): 593–598. doi:10.1038/nature11044.

***In vivo* reprogramming of murine cardiac fibroblasts into induced cardiomyocytes**

Li Qian^{1,2,3}, Yu Huang^{1,2,3}, C. Ian Spencer^{1,2,3}, Amy Foley^{1,2,3}, Vasanth Vedantham^{1,4,5}, Lei Liu^{1,2,3}, Simon J. Conway⁶, Ji-dong Fu^{1,2,3}, and Deepak Srivastava^{1,2,3}

¹Gladstone Institute of Cardiovascular Disease, University of California, San Francisco, CA 94158

²Department of Pediatrics, University of California, San Francisco, CA 94158

³Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94158

⁴Cardiovascular Research Institute, University of California, San Francisco, CA 94158

⁵Department of Medicine, University of California, San Francisco, CA 94158

⁶Developmental Biology and Neonatal Medicine Research Program, Indiana University School of Medicine, Indianapolis, IN 46202, USA

SUMMARY

The reprogramming of adult cells into pluripotent cells or directly into alternative adult cell types holds great promise for regenerative medicine. We reported that cardiac fibroblasts, which represent 50% of the cells in the mammalian heart, can be directly reprogrammed to adult cardiomyocyte-like cells *in vitro* by the addition of Gata4, Mef2c and Tbx5 (GMT). Here, we use genetic lineage-tracing to show that resident non-myocytes in the murine heart can be reprogrammed into cardiomyocyte-like cells *in vivo* by local delivery of GMT after coronary ligation. Induced cardiomyocytes became bi-nucleate, assembled sarcomeres and had cardiomyocyte-like gene expression. Analysis of single cells revealed ventricular cardiomyocyte-like action potentials, beating upon electrical stimulation, and evidence of electrical coupling. *In vivo* delivery of GMT decreased infarct size and modestly attenuated cardiac dysfunction up to 3 months after coronary ligation. Delivery of the pro-angiogenic and fibroblast activating peptide, Thymosin β 4, along with GMT, resulted in further improvements in scar area and cardiac function. These findings demonstrate that cardiac fibroblasts can be reprogrammed into cardiomyocyte-like cells in their native environment for potential regenerative purposes.

Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

Correspondence: Deepak Srivastava, Gladstone Institute of Cardiovascular Disease, 1650 Owens Street, San Francisco, CA 94158, USA, Phone:(415) 734-2716, Fax: (415) 355-0141, dsrivastava@gladstone.ucsf.edu.

AUTHOR CONTRIBUTION

L.Q. designed, supervised and performed the experiments. Y.H. performed all surgeries, echoes and ECGs, and contributed to tissue sectioning and sample preparation. I.S. performed all cellular electrophysiology experiments. A.F. quantified scar size and induced cardiomyocytes and helped with mouse colony maintenance. V.V. helped with isolation of adult cardiomyocytes and implantation of transmitters. S.J.C. provided Periostin-Cre:Rosa26-lacZ mice and supplemental data. J.F. provided initial reagents and technical knowledge and helpful discussion. D.S. designed and supervised the work. L.Q. and D.S. wrote the manuscript.

Keywords

Cellular reprogramming; Cardiomyocyte; Cardiac fibroblast; Thymosin β 4

Heart failure affects over 14 million people worldwide and is a leading cause of death in adults and in children. Because postnatal cardiomyocytes (CMs) have little or no regenerative capacity, current therapies are limited. The introduction of exogenous stem cell-derived CMs holds promise, but also challenges, including delivery, integration, rejection, and cellular maturation^{1–3}. Reprogramming adult fibroblasts into induced pluripotent stem (iPS) cells that are similar to embryonic stem (ES) cells addresses some issues^{4–6}, but others, including efficient directed differentiation into CMs and effective delivery, remain.

A new generation of reprogramming technology involves trans differentiating one adult somatic cell type directly into another^{7–11}. We reported direct reprogramming of fibroblasts into CM-like cells *in vitro* by expressing three transcription factors: Gata4, Mef2c, and Tbx5 (GMT)⁷. As observed in reprogramming to iPS cells, the percentage of fibroblast cells fully reprogrammed to beating CMs *in vitro* was small, but far more were partially reprogrammed, much like pre-iPS cells that can become fully pluripotent with additional stimuli¹². We posited that cardiac fibroblasts may reprogram more fully *in vivo* in their native environment, which might promote survival, maturation, and coupling with neighboring cells. If so, the vast pool of cardiac fibroblasts in the heart could serve as an endogenous source of new CMs for regenerative therapy.

Retroviral delivery of Gata4, Mef2c and Tbx5 into non-myocytes *in vivo*

We used a retroviral system to express GMT, and/or dsRed as a marker, in the hearts of 2-month-old male mice by direct intra myocardial injection. After 2 days, transverse sections of the injected area were prepared and co-stained for dsRed, α -Actinin (a CM marker), and Vimentin (enriched in fibroblasts). No markers are uniquely specific for cardiac fibroblasts, but fibroblasts are known to express Vimentin and the surface markers Thy1 and DDR2¹³. At baseline, it was difficult to detect α -Actinin- or Vimentin-positive cells that also expressed dsRed, suggesting minimal viral uptake, and consistent with the observation that retroviruses only infect actively dividing cells¹⁴.

Fibroblasts are embryo logically distinct from CMs in their origin¹⁵, and following myocardial infarction (MI) become activated, migrate to the injury site, and proliferate^{16,17}. We induced cardiac injury by coronary artery ligation and injected dsRed retrovirus into the myocardium bordering the infarct zone. While cells co-expressing dsRed and α -Actinin were still undetectable, many Vimentin-positive cells were also positive for dsRed (Suppl. Fig. 1). By fluorescence-activated cell sorting (FACS), over 4% of cells ($98,238 \pm 5523$) from the left ventricle of injected hearts were dsRed⁺Thy1⁺ 2 days after injury, suggesting successful delivery of virus into cardiac fibroblasts and possibly other non-myocytes upon injury (Fig. 1a,b). By quantitative (q)PCR, dsRed⁺Thy1⁺-sorted cells expressed 60-fold more Gata4, Mef2c, and Tbx5 than dsRed⁻Thy1⁺ cells, and 6–8-fold more than endogenous CMs (Fig. 1c). A similar number of dsRed⁺Thy1⁻ cells represented other non-myocyte cell

types. Endothelial cells (PECAM⁺) and some peri-vascular cells (NG2⁺) were also transduced by the retrovirus, but hematopoietic (CD34⁺) and pericardial (WT1⁺) cells were not (Suppl. Fig. 1).

Reprogramming of non-myocytes into induced cardiomyocyte-like cells

To determine if new cardiomyocytes could be created *in vivo* from cells other than post-mitotic CMs, we used lineage-tracing experiments to track the origin of putative induced cardiomyocytes (iCMs). To genetically label cells, we used a mouse transgenic line that expresses Cre-recombinase under the promoter of the fibroblast-enriched gene, Periostin^{15,18,19}. When intercrossed with the R26R-lacZ reporter line²⁰, in which β -galactosidase is activated only in Periostin-Cre-expressing cells and their progeny (Fig. 1d-f), we found β -galactosidase activity in many, but not all, cardiac fibroblasts and some endocardial and endothelial cells, as reported^{15,18,19}. Periostin-Cre activity was absent in bone marrow cells (not shown). β -Galactosidase activity was not detected in any cardiomyocytes, even 4 weeks after injury, consistent with thoracic aortic banding studies, confirming that the Periostin-Cre mice faithfully marks descendants of the non-myocyte population, even after infarct (Fig. 1e)^{15,18,19}. Isolation of single CMs from these hearts confirmed absence of β -Galactosidase activity in over 1500 CMs/heart from 6 mice.

In contrast, 4 weeks after MI and retroviral delivery of GMT, numerous β -galactosidase⁺ cells were α -Actinin⁺ in the injured areas, with well-formed sarcomeres and shapes similar to β -galactosidase⁻ myocytes, suggesting they were descendants of cells that once expressed Periostin (Fig. 1f). Similar results were obtained using transgenic mice in which Cre-recombinase was under the control of the fibroblast-specific protein 1 (Fsp1) promoter²¹ to label the non-myocyte population (Fig. 1g and Suppl. Fig. 2a-f). Thus, like MyoD inducing the conversion of cardiac fibroblasts into skeletal muscle *in vivo*²³, GMT appeared to induce the formation of cardiomyocytes *in vivo*. We determined if endothelial and circulating hematopoietic cells marked by Tie2-Cre:R26R-lacZ²² transgenic mice could be reprogrammed to express sarcomeric markers, but found no evidence for such an event (Suppl. Fig. 2g-i).

We formally tested whether retroviral introduction of GMT into non-myocytes could promote cell fusion events in the heart, thereby generating α -Actinin⁺: β -galactosidase⁺ cells. We “pulse-labeled” endogenous CMs in transgenic mice with Cre under inducible control of the α MHC promoter (α MHC-MerCreMer)²⁴ crossed with R26R-EYFP mice (Suppl. Fig. 3). Subsequently, hearts were injured and infected retrovirally with GMT and dsRed to mark infected dividing cells. After 4 weeks, we detected no YFP⁺ cells co-labeled with dsRed in the GMT dsRed-or dsRed-infected hearts (Fig. 2a, b, and Suppl. Fig. 4a). Since pulse-labeling marks only ~80% of endogenous CMs in the uninjured heart and ~60% in the infarct border zone²⁵, we quantified the percentage of YFP⁺ pulse-labeled endogenous CMs at the border area. GMT introduction resulted in a reduced percentage of YFP⁺ endogenous CMs compared to total CMs, indicating that the CMs in this region were refreshed by new iCMs (Fig. 2c). These findings suggest that it is unlikely that cell fusion makes a major contribution to the α -Actinin⁺: β -galactosidase⁺ cell population, although a minor contribution cannot be ruled out.

If α -Actinin⁺: β -galactosidase⁺ cells instead resulted from cellular reprogramming, one might detect progressive stages of reprogramming over time, as cell fusion would yield mature cells soon after fusion without intermediate stages. We therefore analyzed heart sections 1, 2, 3, and 4 weeks after injury and GMT infection, classified cells into four groups based on increasing α -Actinin expression and organization into sarcomeres. The number of α -Actinin⁺: β -galactosidase⁺ cells in the infarct area increased temporally, as did maturity of the cells, with progressive increases in the percentage of cells with well-developed sarcomeres (Suppl. Fig. 5).

To avoid false positives from overlaying cells due to the thickness of the heart sections, we isolated adult CMs at the single-cell level from the infarct/border zone of Periostin-Cre:R26R-lacZ reprogrammed hearts 4 weeks after coronary ligation (Suppl. Fig. 6a). In this preparation, non-myocytes were removed, and cells were assayed 2–4 hours after primary culture. No CMs isolated from dsRed-injected hearts were β -galactosidase⁺ by immunostaining (Fig. 2d). Similarly, CMs from Periostin-Cre:R26R-EYFP mice were all YFP⁻, among the thousands of cells visualized, in agreement with the absence of Periostin-Cre activity in myocytes after injury. In contrast, 35% of cells in the CM preparation from the border/infarct zone were β -galactosidase⁺ after GMT injection (Fig. 2e,f, Suppl. Fig. 6b). Among the β -galactosidase⁺ cells, 98% were also α -Actinin⁺ (Suppl. Fig. 7a-d). Furthermore, in hearts co-injected with GMT and dsRed retrovirus, β -galactosidase⁺ CMs were also positive for dsRed, indicating retroviral infection and their likely origin from non-post-mitotic CMs (Fig. 2g–k).

Most β -galactosidase⁺ cells were large, rod-shaped, and binucleated, closely resembling endogenous CMs that were β -galactosidase⁻ from the same preparation. In addition to α -Actinin, β -galactosidase⁺ cells expressed multiple sarcomeric markers, including Tropomyosin (Fig. 2m), α MHC (Fig. 2n), and cardiac Troponin T (cTnT) (Fig. 2o). Half of the cells had nearly normal sarcomeric structures throughout the cell. The full spectrum of reprogrammed cells, classified by quality of sarcomeric structure, is shown in Suppl. Fig. 7. Characterization of single dsRed⁺ YFP⁻ cells derived from the α -MHC-Mer-Cre-Mer-YFP pulse-labeled reprogrammed hearts revealed good sarcomere formation and expression of α -Actinin, cTnT, and Connexin 43, like dsRed⁻YFP⁺ cells (Suppl. Fig. 4b).

By electron microscopy, about half of the cells from Periostin-Cre:R26R-Tomato reprogrammed hearts exhibited well-organized sarcomeres and mitochondria (Fig. 2p,q), although the sarcomeres were consistently shorter than endogenous CMs and their Z-bands more diffuse. Other Tomato⁺ cells displayed sarcomeric organization in parts of the cell and variable mitochondria organization (Suppl. Fig. 8). For simplicity, we will refer to the β -galactosidase⁺ α -Actinin⁺ CM-like cells as *in vivo* iCMs, based on morphology and sarcomeric structure.

Finally, we assessed the reprogramming of gene expression in iCMs by qPCR, focusing on the mRNA levels of 20 genes normally enriched in mature CMs or cardiac fibroblasts. We tested iCMs isolated from multiple independent hearts alongside cardiac fibroblasts and endogenous CMs. mRNA levels in iCMs were similar to CMs (Fig. 2r and Suppl. Fig. 9),

including the down-regulation of Periostin and Fsp1, consistent with the morphologic changes described earlier.

Cell-cell connectivity and electrophysiology of *in vivo* induced cardiomyocytes

To determine whether iCMs expressed proteins involved in cell-cell communication similar to endogenous CMs, we examined the expression pattern of N-Cadherin, a cell-surface Ca^{2+} -dependent adhesion molecule normally found in intercalated disks within the myocardium²⁶. We found that over 90% of iCMs expressed N-Cadherin, with 60% of cells localizing N-Cadherin appropriately at the cell border (Fig. 3a). Similarly, about 90% of iCMs expressed Connexin 43 (Cx43), the major gap junction protein in the heart that promotes electrical coupling and synchronized contraction of myocytes²⁷. Half of the iCMs expressed Cx43 at high levels with good localization relative to endogenous CMs (Fig. 3b), and in 4% of these cells, the Cx43 localization pattern was almost indistinguishable from endogenous CMs (Fig. 3b). Immunohistochemistry also revealed good cell-border localization of Cx43 in iCMs (Fig. 3c).

To assess the function of cell-to-cell junctions, we imaged the transfer of dyes—microinjected via patch pipettes—between cells, and measured the intercellular transmission of excitation, via Ca^{2+} waves, in small groups of cells isolated from the reprogrammed hearts. Cascade Blue dextran (MW 10,000), which is too large to pass through gap junctions, was retained in the patched iCMs (identified by the lineage marker Periostin-Cre:R26R-Tomato). In contrast, calcein (MW 600) diffused to interconnected endogenous CMs (Fig. 3d). Ca^{2+} waves propagating in an iCM or CM excited intracellular Ca^{2+} release in neighboring cells (Fig. 3e), suggesting that iCM-CM couplings form functional syncytia (see Supplementary Movie 1).

We next performed recordings from a single-cell suspension of CMs isolated from the border/infarct zone of Periostin-Cre:R26R-EYFP mice transduced with GMT, and compared the action potentials generated by iCMs(YFP⁺) and endogenous CMs(YFP⁻) using standard patch-clamp techniques. Approximately 50% of patched iCMs had a physiological resting membrane potential (-70 mV or less) and 50% of iCMs exhibited contractions in response to electrical stimulation, similar to adult ventricular CMs, which are normally quiescent without stimulation (Fig. 3f and Supplementary Movie 2). Electrophysiology parameters assayed were similar to endogenous ventricular CMs (Fig. 3g). In agreement, intracellular calcium releases and cell shortening in iCMs were comparable to endogenous CMs (Fig. 3h). The distribution of action potential durations (APDs) was bimodal in iCMs and CMs, suggesting that reprogrammed cells were incorporated near the epicardial (short APD₉₀) and endocardial (long APD₉₀) sides of ventricular tissue (Suppl. Fig. 10).

In vivo delivery of reprogramming factors improves cardiac function after injury

Since *in vivo* reprogrammed iCMs had contractile potential and electrically coupled with viable endogenous CMs (and other iCMs), we asked whether converting endogenous non-

myocytes into new myocytes translates into partial restoration of heart function after MI. All studies were performed in a blinded fashion, including the retroviral injections, and were decoded only after completion of the measurements. By Evans blue/TTC double staining, the area-at-risk (AAR) and the myocardium infarct size were similar in GMT-or dsRed-injected mice 48 hours after coronary ligation (Suppl. Fig. 12a). Three months post-MI, cardiac function was examined by magnetic resonance imaging (MRI). The fraction of blood ejected with each ventricular contraction (ejection fraction), the volume of blood ejected (stroke volume), and the total cardiac output per minute were significantly improved in GMT-infected mice, particularly the stroke volume and cardiac output, possibly due to cardiac enlargement (Fig. 4a). To determine the time course of these improvements, other mice underwent serial high-resolution two-dimensional echocardiography 1 day before MI, and 3 days, 1-, 4-, 8-, and 12-weeks post-MI (Suppl. Fig. 11b-d). All mice showed a comparable reduction in left ventricular function after coronary artery ligation (Suppl. Fig. 11c). Although different imaging approaches yield different absolute value norms, the overarching trends observed by echocardiography were similar to our MRI findings, in that functional improvements for all parameters were statistically significant 8 and 12 weeks post-injection (Suppl. Fig. 11c).

We next performed qPCR to monitor the expression levels of atrial natriuretic factor, brain natriuretic peptide and tenascin C in injured and control hearts. We found that MI led to the upregulation of all three peptides, but this upregulation was attenuated in GMT-injected infarcted hearts (Fig. 4b). Expression levels of collagen genes, which were increased in uninfected MI hearts, were also partially restored by injecting GMT (Fig. 4c). Furthermore, the scar area calculated from 16 sections at four levels of the heart was significantly smaller 8 weeks after MI in the GMT-treated group. To determine if the muscle cells in the scar area were reprogrammed iCMs, we repeated the experiments in Periostin-Cre:R26R-LacZ transgenic mice. α -Actinin⁺ cells in the scar area were also β -Galactosidase positive, suggesting that they were newly born iCMs of non-myocyte origin (Fig. 4e). Vascular density was significantly increased in the border zone of reprogrammed hearts at 8 weeks (Suppl. Fig. 12). Electro cardiographic (ECG) studies (telemetry) over a 24-hour period did not indicate evidence for more arrhythmias in GMT- versus dsRed-injected control mice, and no mice suffered sudden death (not shown).

Thymosin β 4 enhances the delivery of reprogramming factors and further improves cardiac function

We hypothesized that infecting more Thy1⁺ cells would enhance functional improvement. Thymosin β 4, a 43-amino-acid G-actin monomer-binding protein, promotes cell migration^{28,29}, cardiac cell survival^{28,30} and activates epicardial cells to become more proliferative and yield more cardiac fibroblasts and endothelial cells^{31,32}. It also improves cardiac function and decreases scar size after MI²⁸. To test cardiac fibroblast migration, we used a cardiac explant migration assay^{7,28}. The average time for fibroblasts to migrate from adult heart explants was 3 weeks; however, Thymosin β 4 treatment led to equivalent fibroblast migration within 2 weeks and within only 3 days in heart explants taken after MI (Fig. 5a). Similarly, Vimentin⁺ cell proliferation was even more pronounced post-MI in the

presence of Thymosin β 4, as marked by phosphohistone H3 (Suppl. Fig. 13b). The percentage of Thy1⁺ (Suppl. Fig. 13c) or Vimentin⁺ (Suppl. Fig. 14a) cells infected by retrovirus after MI doubled upon intra myocardial Thymosin β 4 injection ($316,607 \pm 17,799$ dsRed⁺ cells averaged from three hearts). GMT did not increase the number of cardiac fibroblasts (Suppl. Fig. 13d). Delivering GMT-expressing retrovirus to more cells by adding Thymosin β 4 yielded more β Gal⁺ iCMs compared to total CMs in single-cell CM culture from the infarct/border zone of Periostin-Cre:R26R-lacZ hearts (51% vs. 35%) (Suppl. Fig. 13e). However, we observed no change in the degree or efficiency of *in vivo* reprogramming, with the percentage of iCMs generated from the total GMT-infected cell population remaining at ~12% (Suppl. Fig. 13e, Suppl. Fig. 14b).

Injecting Thymosin β 4 immediately after ligation improved cardiac function, as reported^{28,30}. Co-injecting Thymosin β 4 and GMT further improved ejection fraction and cardiac output 8 weeks after infarction (Suppl. Fig. 13f and Suppl. Fig. 14d,e). Furthermore, co-injecting Thymosin β 4 and GMT caused less scarring than injecting either alone (Suppl. Fig. 13g), despite similar areas at risk and initial infarct sizes (Suppl. Fig. 14c).

Discussion

We show that upon cardiac injury, resident cardiac non-myocytes—primarily fibroblasts—can be converted into CM-like cells *in vivo* following local delivery of GMT by retroviral-mediated gene transfer. *In vivo* cardiac reprogramming occurred with similar initial efficiency as observed *in vitro* (10–15%). However, *in vivo* iCMs were more fully reprogrammed and more closely resembled endogenous CMs than their cultured counterparts. This may result from factors within the native microenvironment—including extracellular matrix, secreted proteins, and tissue stiffness—that further enhance reprogramming. Improved cardiac function may be explained by the diversion of a small percentage of fibroblasts into new CM-like cells, suggesting functional integration of these muscle cells. Although non-myocytes convert to iCMs to help regenerate the damaged heart, alteration of fibroblast behavior by GMT may contribute to the effects on scar formation and cardiac function. While it is difficult to separate the relative contributions of new muscle formation and other non-cell-autonomous effects, non-myocyte reprogramming in the heart appears to be beneficial for cardiac function. Optimizing gene delivery to more cells would likely enhance functional benefits.

Improvement upon Thymosin β 4 addition is in agreement with the notion that increasing the delivery of GMT to more cells could enhance cardiac repair. Pre-treating hearts with Thymosin β 4 several days before injury resulted in a small population of epicardial-derived cells that could behave as myocyte precursors, but not if Thymosin β 4 was given at the time of injury³³. Nevertheless, transduction of GMT into these progenitors, or other rare progenitors yet to be identified, might promote their differentiation into cardiomyocytes. Since Thymosin β 4 is also pro-angiogenic^{31,32}, the cooperativity between GMT and Thymosin β 4 may be multi-faceted and will be interesting to explore.

The ability to regenerate adult heart tissue from endogenous cells is a promising approach to treating cardiac disease that may face fewer obstacles to clinical translation than other

approaches. Improving the delivery of reprogramming factors, using small molecules and epigenetic modulators, and conducting trials in large animals will be important to refine the technology and assess its safety and efficacy, particularly regarding arrhythmias.

METHODS SUMMARY

Retroviruses

Retroviruses were generated as described⁷ using pMXs retroviral vectors containing coding regions of Gata4, Mef2c, Tbx5, and dsRed. Ultra-high titer virus ($>1 \times 10^{10}$ plaque-forming units (p.f.u) per ml) was obtained by ultracentrifugation.

Animals, surgery, echocardiography and electrocardiography

Periostin (Postn)-Cre:R26R-lacZ or Fsp1-Cre:R26R-lacZ mice were obtained by crossing Periostin-Cre mice¹⁹ or Fsp1-Cre mice²¹ and R26R-lacZ mice²⁰. Postn-Cre:R26R-EYFP or α MHC-MerCreMer:R26R-EYFP mice were obtained by crossing Periostin-Cre or α MHC-MerCreMer²⁴ mice and R26R-EYFP mice. Postn-Cre:R26R-Tomato mice were obtained by crossing Periostin-Cre mice and R26R-Tomato mice. Surgeries and subsequent analyses were performed blinded to genotype and intervention. MI was induced by permanent ligation of the left anterior descending artery (LAD) as described³⁴. A pool of concentrated virus (GMT or GMTR) was mixed, and 10 μ l of mixed virus plus 10 μ l of PBS or 40 ng/ μ l Thymosin β 4 were injected along the boundary between the infarct and border zones. Mouse echocardiography and surface electrocardiography were performed as described³⁴. All mouse work was done with approval of the UCSF animal care oversight committee.

Immunohistochemistry, immunocytochemistry, and electron microscopy

Immunohistochemistry, immunocytochemistry, and electron microscopy (EM) were performed as described^{34,35}. Scar size was determined by Masson-Trichrome staining^{28,34}. The AAR and myocardial infarct size were determined by Evans Blue/triphenyltetrazolium chlorid labeling³⁴.

Isolation of adult cardiomyocytes, single-cell patch-clamp, and cardiac fibroblast migration assays

Adult cardiomyocytes were isolated as described with minor modifications³⁶. Single-cell patch clamp recordings were performed as described³⁷. Migration assays were performed according to published protocols^{7,28}.

FACS and quantitative RT-PCR

Dissociated cardiac cells were stained with APC-conjugated anti-Thy1 antibody (eBioscience). Stained cells were sorted by FACS Aria2 (BD) and RNA extracted in TRizol (Invitrogen). qPCR was performed using ABI 7900HT (TaqMan, Applied Biosystems).

Statistics

Differences between groups were examined for statistical significance using unpaired student's *t*-tests or ANOVA. $p < 0.05$ was regarded as significant.

METHODS

Retrovirus generation, concentration, and titration

Retroviruses were generated as described. To generate virus, pMXs retroviral vectors containing the coding regions of Gata4, Mef2c, Tbx5, and dsRed were transfected into Plat-E cells using Fugene 6 (Roche). 48 hours after transfection, virus-containing supernatants were collected and concentrated by standard ultracentrifugation. Retroviral titration was performed using the Retro-X qRT-PCR Titration Kit (Clontech), as per the manufacturer's protocols. Ultra-high titer virus ($>1 \times 10^{10}$ plaque-forming units [p.f.u] per ml) was resuspended in PBS. After verification of high transduction efficiency in cell culture ($>95\%$), a large number of small stock aliquots (10 μ l) were made and frozen at -80°C to ensure consistency among experiments. After one freeze-thaw cycle, titrations were repeated to ensure that active virus was maintained at the desired 1×10^{10} p.f.u concentration for *in vivo* injection.

Mouse lines

Periostin (Postn)-Cre:R26R-lacZ mice were obtained by crossing Postn-Cre mice and Rosa26-lacZ mice. Postn-Cre:R26R-YFP mice were obtained by crossing Postn-Cre mice and Rosa26-EYFP mice, and Postn-Cre:R26R-Tomato mice were obtained by crossing Postn-Cre mice and Rosa26-Tomato mice. All transgenic lines were maintained by crossing with C57BL6 mice (Charles River) for immunohistochemistry (IHC) and single cell isolation. BALB/C mice (Charles River) were used for all functional studies after LAD and virus injection. Fsp1-Cre, Tie2-Cre and Myh6-MerCreMer mice were obtained from Jackson Labs, and lines were validated before further breeding. Fsp1-R26R, Tie2-R26R, and Myh6-MerCreMer-YFP mice were obtained by crossing Fsp1-Cre, Tie2-Cre or Myh6-MerCreMer mice to R26R-lacZ or R26R-EYFP mice. Efficiency of Cre recombination induction for Myh6-MerCreMerYFP was tested by IHC for YFP after injection of various doses of tamoxifen. To "pulse" label the pre-existing CMs, adult Myh6-MerCreMerYFP mice (8–12 weeks old) were treated with tamoxifen (Sigma) by intraperitoneal injection once a day for 5 days at a dosage of 20 mg/kg/day. GMT delivery and coronary artery ligation were performed 2 days afterwards.

Mouse myocardial infarction model and *in vivo* delivery of virus and Thymosin β 4

The animal protocol for surgery was approved by institutional guidelines (UCSF Institutional Animal Care and Use Committee). All surgeries and subsequent analyses were performed blinded for genotype and intervention. Mice were anesthetized with 2.4% isoflurane/97.6% oxygen and placed in a supine position on a heating pad (37°C). Animals were intubated with a 19 G stump needle and ventilated with room air using a MiniVent Type 845 mouse ventilator (Hugo Sachs Elektronik-Harvard Apparatus, Germany; stroke volume 250 μ l, respiratory rate 120 breaths/minute). MI was induced by permanent ligation of the left anterior descending artery (LAD) with a 7-0 prolene suture as described²⁸. Sham-operated animals served as surgical controls and were subjected to the same procedures as the experimental animals with the exception that the LAD was not ligated. A pool of concentrated virus (Gata4/Mef2c/Tbx5 [GMT] or Gata4/Mef2c/Tbx5/dsRed [GMTR]) was mixed, and 10 μ l of mixed virus plus 10 μ l of PBS or 40 ng/ μ l Thymosin β 4 was injected

into the myocardium through an insulin syringe with an incorporated 29G needle (BD). Injection with a full dosage was carried out along the boundary between the infarct zone (IZ) and border zone (BZ) based on the blanched infarct area after coronary artery occlusion. After injection, the chest was closed with sutures and the mouse was allowed to recover with the mouse ventilator and heating pad. All surgical procedures were performed under aseptic conditions. At 2 days and 1, 2, 4, 8, and 12 weeks after occlusion and viral delivery, the hearts were removed for perfusion fix in 4% paraformaldehyde (PFA) for preparation of paraffin sections for structural analysis and immunohistochemistry or in 0.5% PFA in 5% sucrose followed by cryostat sectioning for immunofluorescent staining. Concurrently, heart tissues within the infarct zone (IZ), border zone (BZ) and non-ischemic zone distal to the infarct zone (DZ) were dissected for RNA or protein isolation.

Determination of the area at risk (AAR) and myocardial infarct size

At 48 hours after coronary ligation, the mice were anesthetized and cannulated with tubing. Evans Blue (2%, Sigma) was perfused into the aorta, thus all myocardial tissue was stained blue except the AAR. The LV was isolated and cut into four ~1 mm pieces with the first cut at the ligation level. LV slices were stained in 1.5% triphenyltetrazolium chloride (TTC) for 30 min at 37 C, and then fixed in 4% PFA overnight at 4 C. The area of infarction was demarcated as a white area, while viable myocardium was stained red. Photographs were taken from both sides of each section. The AAR and the infarct area were determined via planimetry with the computer software ImagePro (Biorad). Infarct size was calculated as the percentage of myocardial infarction compared with the AAR using the described methodology³⁸.

Determination of scar size

Standard Masson-Trichrome staining was performed on hearts 8 weeks post-viral delivery and coronary artery ligation. To determine the scar size, we used ImagePro software to measure the scar area (blue) and healthy area (red) on transverse sections spanning four levels (50 mm between two levels, with the first level starting right below the ligation) within the left ventricle of a MI heart. From each level, we measured four slices of tissues as technical quadruplicates (for a total of 16 sections). The averaged number was used for statistics and comparison. The measurements and calculations were conducted in a blinded manner.

Mouse echocardiography

Echocardiography was performed by the Vevo 770 High-Resolution Micro-Imaging System (VisualSonics, Toronto, Canada) with a 15-MHz linear array ultrasound transducer. The left ventricle (LV) was assessed in both parasternal long-axis and short-axis views at a frame rate of 120 Hz. End-systole or end-diastole was defined as the phase in which the smallest or largest area of LV, respectively, was obtained and used for ejection fraction measurement. Left ventricular end-systolic diameter (LVESD) and left ventricular end-diastolic diameter (LVEDD) were measured from the LV M-mode tracing with a sweep speed of 50 mm/s at the papillary muscle level for calculating the shortening fraction. B-mode was used for two-dimensional measurements of end systolic and end diastolic dimensions.

Mouse surface electrocardiography

Mice were anesthetized with 1.75% isoflurane at a core temperature of 37–38°C. Four needle electrodes (AD Instruments) were placed subcutaneously in standard limb lead configurations. For each mouse, 10–20 seconds of continuous signals were sampled at 10 KHz in each lead configuration with a PowerLab4/30 interface (AD Instruments). Data analysis was performed offline with electronic calipers on averaged beats (Chart5Pro v5.4.2, AD Instruments).

Mouse awake electrocardiography (telemetry)

To record awake electrocardiograms in six reprogrammed post-MI mice and six control post-MI mice, transmitters were surgically implanted according to the manufacturer's instructions (Data Sciences International, St. Paul, MN). After a 3-day recovery period, the electrocardiogram was recorded continuously for 48 hours in each mouse. Tracings were analyzed off-line and were scored by a blinded investigator for the presence and frequency of arrhythmias.

Magnetic resonance imaging

MRI was performed on a Varian DirectDrive 7T small-animal scanner (Varian, Palo Alto, CA, USA). Each mouse was anesthetized by inhalation of 2% isoflurane/98% oxygen administered via an MR-compatible mobile inhalation anesthesia system (Vet Equip, Pleasanton, CA, USA). The mice were put in supine position on a homemade heating bed to keep the temperature at 37°C. Two ECG leads were inserted into the right front and left rear leg. ECG waveforms were monitored with a small animal monitoring and gating system (SA instruments, Stony Brook, NY, USA). The mouse was then placed into a homemade 1H birdcage coil with an inner diameter of 32 mm. A group of ECG- (R-wave rising edge) triggered spin echo scout images were acquired first to define the oblique plane of the short-axis. Then an ECG-triggered 2D gradient echo sequence with an echo time of 2.75 ms, repetition time of 200 ms and a flip angle of 45° was used to obtain nine short-axis images at 12 or 13 phases per cardiac cycle. Each scan consisted of 8–9 contiguous slices spanning the LV from apex to base with 1-mm thickness, a matrix size of 128×128, a field of view of 25.6 × 25.6 mm, and four averages.

Isolation of adult cardiomyocytes

Adult cardiomyocyte isolation was performed as described with minor modifications³⁶. Briefly, adult mice were anesthetized with isoflurane and mechanically ventilated. Hearts were removed and perfused retrogradely via aortic cannulation with a constant flow of 3 ml/min in a Langendorf apparatus. Hearts were perfused at 37°C for 5 min with supplemented Wittenberg Isolation Medium (WIM) containing (in mM): 116 NaCl, 5.4 KCl, 6.7 MgCl₂, 12 glucose, 2 glutamine, 3.5 NaHCO₃, 1.5 KH₂PO₄, 1.0 NaH₂PO₄, 21 HEPES, with 1.5 nM insulin, essential vitamins (GIBCO), and essential amino acids (GIBCO) (pH 7.4), followed by digestion solution (WIM, supplemented with 0.8 mg/ml collagenase II and 10 μM CaCl₂) for 10 min (4 min for paired CMs that were used in cell-cell coupling experiments). Hearts were then removed from the Langendorf apparatus while intact (with tissues loosely connected). Desired areas (i.e. border/infarct zone) were then micro-dissected

under the microscope, followed by mechanical dissociation, triturating, and resuspension in a low-calcium solution (WIM, supplemented with 5 mg/ml BSA, 10 mM Taurine, and 150 μ M CaCl_2). Cells were then spun at low speed, supernatant was removed, and calcium was gradually reintroduced through a series of washes. For electrophysiology experiments, cells were used on the same day as isolation and until recording were stored at room temperature in M199 (Gibco) supplemented with 5 mM creatine, 2 mM L-carnitine, 5 mM Taurine, and 1.5 nM insulin. For immunohistochemistry, cells were plated onto laminin-coated culture slides, allowed to adhere, and fixed on the day of isolation. For EM or qPCR, iCMs were selected manually by micro-pipette based on the presence of Periostin-Cre:R26R-YFP/ Tomato signal under the fluorescent microscope right after isolation.

Cardiac fibroblast migration assay

The migration assay was performed according to the explant culture protocol as described. In brief, isolated adult mouse hearts were minced into small pieces less than 1 mm³ in size. The explants were plated on gelatin-coated dishes and cultured in explant medium (IMDM/20%FBS) until fibroblasts migrated out from minced tissue. The time required for 10 heart pieces to have migratory fibroblasts surrounding them were recorded.

FACS analyses and sorting

At 48 hours after LAD and viral introduction, hearts were removed and minced into small pieces less than 1 mm³ in size. Blood cells and debris were removed by several washings of PBS. Minced cardiac tissues were digested in an eppendorf tube and shaken with glass beads in enzyme buffer (Collagenase/Dispase[Roche] plus DNaseI [Roche]) at 37°C. After passing through a 40- μ m cell strainer, dissociated cardiac cells were stained with APC-conjugated anti-Thy1 antibody (eBioscience) for 30 min at room temperature. After washing with PBS twice, stained cells were sorted by FACSAria2 (BD).

Immunohistochemistry

For immunofluorescence, after perfusion-fixed hearts were taken out and fixed in 0.5% paraformaldehyde(PFA) overnight, ventricles below the ligation were embedded in OCT compound and frozen in liquid nitrogen. Sections were blocked in Universal Blocking Buffer (BioGenex) for 10 min, and then stained with primary antibodies against α -Actinin (Sigma Aldrich), Vimentin (Progen), β Gal (Abcam), pH3 (Millipore), RFP (Biovision), Thy1 (BD), CD34 (Abcam), WT1 (Abcam), PECAM (BD), NG2 (Millipore), and GFP (Invitrogen) for 1 hour at room temperature. After washing three times with PBST (PBS + 0.1% Triton), sections were incubated in secondary antibodies for 1 hour followed by washing an additional three times with PBST. Finally, the sections were mounted in Vectashield with DAPI (Vector Laboratories).

Immunocytochemistry

Isolated cells plated on chamber slides were fixed in 4% PFA at 4°C overnight and washed with PBS twice. Cells were then incubated with primary antibodies against sarcomeric α -Actinin (Sigma Aldrich), cardiac TnT (Thermo Scientific), RFP (Biovision), Tropomyocin (Hybridoma Bank), MF20 (Hybridoma Bank), Connexin43 (Sigma Aldrich), N-Cadherin

(Invitrogen), β -Gal (Abcam), smooth muscle actin (Sigma Aldrich), and Vimentin (Progen) for 1 hour at room temperature and washed with PBS three times, then incubated with secondary IgG antibodies conjugated to Cy488 or 594 (Jackson ImmunoResearch) for 30 min. After washing with PBS, cells were mounted in Vectashield with DAPI.

Electron Microscopy (EM)

For electron microscopy, cells were fixed in 2% glutaraldehyde, 1% paraformaldehyde in 0.1M sodium cacodylate buffer, pH 7.4, post fixed in 2% osmium tetroxide in the same buffer, *en block* stained with 2% aqueous uranyl acetate, dehydrated in acetone, infiltrated, and embedded in LX-112 resin (Ladd Research Industries, Burlington, VT). Samples were ultrathin sectioned on a Reichert Ultracut S ultramicrotome and counter stained with 0.8% lead citrate. Grids were examined on a JEOL JEM-1230 transmission electron microscope (JEOL USA, Inc., Peabody, MA) and photographed with the Gatan Ultrascan 1000 digital camera (Gatan Inc., Warrendale, PA).

Action potential recordings

Isolated myocytes suspended in tissue culture medium were transferred to a superfusion chamber (RC-26GLP; Warner Instruments, Hamden, CT) on the stage of a Nikon TiS inverted fluorescence microscope equipped with a dual wavelength microfluorometer (IonOptix, Milton, MA). Myocytes isolated from either Periostin-Cre:R26R-YFP or Periostin-Cre:R26R-Tomato hearts after GMT infection were identified as control cardiomyocytes (CMs) or induced CMs (iCMs) on the basis of Tomato fluorescence (Texas red optics with exciter 560 ± 55 nm, emitter 645 ± 75 nm) or YFP (standard FITC optics), and were chosen for study if they lacked spontaneous beating and partial contractures. The myocytes were whole-cell patch-clamped using an Axopatch 200B amplifier and pClamp software (Molecular Devices Inc., Sunnyvale, CA). Patch electrodes of 2–5 MegOhms (1B-150F; WPI, Sarasota, FL) were filled with intracellular solution containing 120mM KCl, 20mM NaHEPES, 10mM MgATP, 5mM K₂EGTA (or 0.1 mM), 2mM MgCl₂, and adjusted to pH 7.1 with KOH. The cells were superfused with a modified Tyrode's extracellular solution containing 137mM NaCl, 10mM NaHEPES, 10mM dextrose, 5mM KCl, 2mM CaCl₂, 1mM MgCl₂, adjusted to pH 7.4 with NaOH. After gigaOhm seal formation, whole-cell access to the myocyte was established by applying brief pressure pulses, and the amplifier was switched to current clamp mode, where upon the cell's resting potential developed. Action potentials were stimulated at 0.33 Hz using 2 nA, 2 ms current pulses applied through the patch pipette, and were signal averaged in tens. All membrane potentials were corrected for a -5.6 mV liquid junction potential determined via pClamp software. Finally, the amplifier was switched back to voltage clamp mode to identify individual ion channel currents as required. In some experiments, the concentration of K₂EGTA in the intracellular solution was reduced to 0.1 mM to permit excitation-contraction (EC) coupling to occur, and 100 μ M K5Fluo-4 (Invitrogen Corp, Carlsbad, CA) was added to define the presence of cytosolic Ca²⁺ transients during action potentials. Electrophysiology data were digitized at 5 kHz and low-pass filtered at 2 kHz. Analysis was performed using pClamp, Microsoft Excel, and Origin (OriginLab, Northampton, MA) software. Action potential duration was measured from the point of maximum

depolarizing voltage change (+dV/dtMax) to 50, 70, and 90% repolarization. Unless stated, experiments were performed at room temperature (21°C).

Field stimulation experiments

Isolated myocytes were loaded with Fluo-4 for 30 min at room temperature before being transferred to the superfusion chamber. The loading solution contained a 1:10 mixture of 5 mM Fluo-4 AM in dry DMSO and PowerloadTM concentrate (Invitrogen Corp) which was diluted 100-fold into extracellular Tyrode's solution containing suspended myocytes. An additional twenty minutes was allowed for de-esterification before commencing recordings. Contractions and Ca²⁺ transients were evoked by applying voltage pulses at 0.33 Hz, between platinum wires placed on either side of the cell of interest and connected to a field stimulator (IonOptix, Myopacer). The pulses were of 2 ms duration and set at 150% of the threshold required to elicit twitches. Fluo-4 fluorescence transients were recorded via a standard filter set (#49011 ET, Chroma Technology Corp., Bellows Falls, VT) in batches of 10 to enable signal averaging. Between stimuli, the fluorescence excitation light was blocked by an electromechanical shutter (CS35; Vincent Associates, Rochester, NY). Resting fluorescence was recorded after cessation of pacing, and background light was obtained after picking up and removing the cell from the field of view with a patch electrode at the end of the experiment. The Ca²⁺ transients were calibrated using the pseudo-ratio method³⁹, assuming an *in situ* dissociation constant of 1.1 μM for Fluo-4⁴⁰. Contractions were optically recorded simultaneously with Ca²⁺ transients by illuminating the cell of interest in red light ($\lambda > 665$ nm) subsequently directed to a CCD camera (IonOptix Myocam). The cell length signals were converted to voltage via a video motion director (VED 205; Crescent Electronics, Sandy, UT) and contraction amplitudes from different myocytes were normalized by calculating the percent change in cell length.

Determination of cell-to-cell coupling

In experiments to assess the interconnectivity between iCMs and CMs, the whole-cell patch clamp method was used to introduce a gap junction-permeable (i.e., mobile) and an impermeable (i.e., immobile) dye into the same cell of interest within a small group of apparently coupled isolated myocytes (n=5 groups from 5 independent hearts). The mobile dye was calcein (5mM), and the immobile dye was 1 mM dextran-conjugated Cascade Blue (M.W. 10000). The immobile dye was chosen to be well separated spectrally, both from calcein and from tomato, which was used for labeling iCMs (Invitrogen Corp). The dye pair was included in standard intracellular solution (containing 5 mM EGTA) and cytoplasmic loading was allowed to proceed for 2 min, after which the patch electrode was withdrawn from the patched myocyte. The sarcolemma of the cell re-sealed after pulling off the pipette, aided by high EGTA levels in the filling solution, thereby trapping the dyes in the cytoplasm. Blue fluorescence from the immobile indicator was excited at 365±40 nm, while calcein fluorescence was excited at 470±40 nm. Fluorescent images were recorded using IonOptix Myocam via a video frame grabber (#166VCB, Hauppauge, Hauppauge, NY) for processing using ImageJ software.

The functionality of cell-to-cell junctions was investigated by imaging the intercellular transmission of Ca²⁺ waves and excitation between myocytes pre-loaded with Fluo-4 AM as

detailed above for the field-stimulation studies. Superfusion with 2 μM ouabain for 5–10 min was employed to induce intracellular Ca^{2+} overload accompanied by Ca^{2+} wave activity, and videomicroscopy revealed the spatiotemporal relationships of Ca^{2+} waves translocating within and between the individual cells imaged in small, adherent groups ($n=6$ groups from 5 independent hearts).

Quantitative real-time PCR

iCMs were manually sorted based on the presence of fluorescent lineage markers. ~100 iCMs were pooled for RNA isolation. Similarly, ~100 endogenous CMs isolated using the standard Langendorf apparatus (see above) and ~500 cardiac fibroblasts using the migration assay (see above) were prepared for RNA isolation. RNA was extracted by the TRizol method (Invitrogen). RT-PCR was performed using the Superscript III first-strand synthesis system (Invitrogen). qPCR was performed using the ABI 7900HT (TaqMan, Applied Biosystems) as per the manufacturer's protocols. Optimized primers from Taqman Gene Expression Array were used.

Statistical analyses

Differences between groups were examined for statistical significance using unpaired student's t-test or ANOVA. A p -value < 0.05 was regarded as significant. Error bars indicate standard error of the mean (SEM).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We are grateful for expert technical assistance from the Gladstone Histology Core (C. Miller), Gladstone Genomics Core (L. Ta, Y. Hao, B. Chadwick), UCSF MRI Core (M. Wendland, J. Hawkins) and Laboratory for Cell Analysis at UCSF (S. Elmes). We thank all the members of the Srivastava lab for helpful discussions; G. Howard and B. Taylor for editorial help; and B. Bruneau and B. Conklin for helpful discussions and critical reviews of the manuscript. We also thank J. Nerbonne, N. Foeger, and members of the Nerbonne laboratory for assistance with the adult myocyte isolation protocol. L.Q. is a postdoctoral scholar of the California Institute for Regenerative Medicine (CIRM). V.V. is supported by grants from the GlaxoSmithKline Research and Education Foundation and the NIH/NHLBI (K08HL101989). J.F. is supported by a postdoctoral fellowship from American Heart Association. S.J.C. was supported by R01 HL060714 from NHLBI/NIH. D.S. was supported by grants from NHLBI/NIH, CIRM, the Younger Family Foundation, Roddenberry Foundation and Whittier Foundation. This work was supported by NIH/NCRR grant (C06 RR018928) to the Gladstone Institutes. D.S. is a member of the Scientific Advisory Board of iPierian, Inc., and RegeneRx Pharmaceuticals.

References

1. Murry CE, Keller G. Differentiation of embryonic stem cells to clinically relevant populations: Lessons from embryonic development. *Cell*. 2008; 132:661–680. [PubMed: 18295582]
2. Passier R, van Laake LW, Mummery CL. Stem-cell-based therapy and lessons from the heart. *Nature*. 2008; 453:322–329. [PubMed: 18480813]
3. Srivastava D, Ivey KN. Potential of stem-cell-based therapies for heart disease. *Nature*. 2006; 441:1097–1099. [PubMed: 16810246]
4. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell*. 2006; 126:663–676. [PubMed: 16904174]

5. Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell*. 2007; 131:861–872. [PubMed: 18035408]
6. Yamanaka S, Blau HM. Nuclear reprogramming to a pluripotent state by three approaches. *Nature*. 2010; 465:704–712. [PubMed: 20535199]
7. Ieda M, et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. *Cell*. 2010; 142:375–386. [PubMed: 20691899]
8. Szabo E, et al. Direct conversion of human fibroblasts to multilineage blood progenitors. *Nature*. 2010; 468:521–526. [PubMed: 21057492]
9. Vierbuchen T, et al. Direct conversion of fibroblasts to functional neurons by defined factors. *Nature*. 2010; 463:1035–1041. [PubMed: 20107439]
10. Zhou Q, Brown J, Kanarek A, Rajagopal J, Melton DA. In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. *Nature*. 2008; 455:627–632. [PubMed: 18754011]
11. Huang P, et al. Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. *Nature*. 2011; 475:386–389. [PubMed: 21562492]
12. Silva J, et al. Promotion of reprogramming to ground state pluripotency by signal inhibition. *PLoS Biol*. 2008; 6:e253. [PubMed: 18942890]
13. Ieda M, et al. Cardiac fibroblasts regulate myocardial proliferation through beta1 integrin signaling. *Dev Cell*. 2009; 16:233–244. [PubMed: 19217425]
14. Byun J, et al. Myocardial injury-induced fibroblast proliferation facilitates retroviral-mediated gene transfer to the rat heart in vivo. *J Gene Med*. 2000; 2:2–10. [PubMed: 10765500]
15. Snider P, et al. Origin of cardiac fibroblasts and the role of periostin. *Circ Res*. 2009; 105:934–947. [PubMed: 19893021]
16. Baudino TA, Carver W, Giles W, Borg TK. Cardiac fibroblasts: Friend or foe? *Am J Physiol Heart Circ Physiol*. 2006; 291:H1015–1026. [PubMed: 16617141]
17. Camelliti P, Borg TK, Kohl P. Structural and functional characterisation of cardiac fibroblasts. *Cardiovasc Res*. 2005; 65:40–51. [PubMed: 15621032]
18. Snider P, et al. Periostin is required for maturation and extracellular matrix stabilization of noncardiomyocyte lineages of the heart. *Circ Res*. 2008; 102:752–760. [PubMed: 18296617]
19. Takeda N, et al. Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. *J Clin Invest*. 2010; 120:254–265. [PubMed: 20038803]
20. Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. *Nat Genet*. 1999; 21:70–71. [PubMed: 9916792]
21. Bhowmick NA, et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. *Science*. 2004; 303:848–851. [PubMed: 14764882]
22. Kisanuki YY, et al. Tie2-Cre transgenic mice: A new model for endothelial cell-lineage analysis in vivo. *Dev Biol*. 2001; 230:230–242. [PubMed: 11161575]
23. Murry CE, Kay MA, Bartosek T, Hauschka SD, Schwartz SM. Muscle differentiation during repair of myocardial necrosis in rats via gene transfer with MyoD. *J Clin Invest*. 1996; 98:2209–2217. [PubMed: 8941636]
24. Sohal DS, et al. Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. *Circ Res*. 2001; 89:20–25. [PubMed: 11440973]
25. Hsieh PC, et al. Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. *Nat Med*. 2007; 13:970–974. [PubMed: 17660827]
26. Li J, et al. Cardiac-specific loss of N-cadherin leads to alteration in connexins with conduction slowing and arrhythmogenesis. *Circ Res*. 2005; 97:474–481. [PubMed: 16100040]
27. Saffitz JE, Laing JG, Yamada KA. Connexin expression and turnover: Implications for cardiac excitability. *Circ Res*. 2000; 86:723–728. [PubMed: 10764404]
28. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. *Nature*. 2004; 432:466–472. [PubMed: 15565145]
29. Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: Actin-sequestering protein moonlights to repair injured tissues. *Trends Mol Med*. 2005; 11:421–429. [PubMed: 16099219]

30. Hinkel R, et al. Thymosin beta4 is an essential paracrine factor of embryonic endothelial progenitor cell-mediated cardioprotection. *Circulation*. 2008; 117:2232–2240. [PubMed: 18427126]
31. Smart N, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. *Nature*. 2007; 445:177–182. [PubMed: 17108969]
32. Bock-Marquette I, et al. Thymosin beta4 mediated PKC activation is essential to initiate the embryonic coronary developmental program and epicardial progenitor cell activation in adult mice in vivo. *J Mol Cell Cardiol*. 2009; 46:728–738. [PubMed: 19358334]
33. Smart N, et al. De novo cardiomyocytes from within the activated adult heart after injury. *Nature*. 2011; 474:640–644. [PubMed: 21654746]
34. Qian L, et al. miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes. *J Exp Med*. 2011
35. Larsen TH, Saetersdal T, Grong K. The ultrastructure of the myocyte in different regions of experimental infarcts in the cat heart. *Res Exp Med*. 1986; 186:295–306.
36. Xu H, Guo W, Nerbonne JM. Four kinetically distinct depolarization-activated K⁺ currents in adult mouse ventricular myocytes. *J Gen Physiol*. 1999; 113:661–678. [PubMed: 10228181]
37. Fenske S, et al. HCN3 contributes to the ventricular action potential waveform in the murine heart. *Circ Res*. 2011; 109:1015–1023. [PubMed: 21903939]
38. Kurrelmeyer KM, et al. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. *Proc Natl Acad Sci USA*. 2000; 97:5456–5461. [PubMed: 10779546]
39. Cheng H, Lederer WJ, Cannell MB. Calcium sparks: Elementary events underlying excitation-contraction coupling in heart muscle. *Science*. 1993; 262:740–744. [PubMed: 8235594]
40. Ljubojevic S, et al. In situ calibration of nucleoplasmic versus cytoplasmic Ca⁽²⁾⁺ concentration in adult cardiomyocytes. *Biophysical J*. 2011; 100:2356–2366.




Figure 1. Genetic lineage tracing demonstrates *in vivo* reprogramming of cardiac fibroblasts to cardiomyocyte-like cells

a, Quantification of FACS analyses for Thy1⁺ cells from sham-operated mouse hearts or hearts 2 days after myocardial infarction (MI) (n=3, *p<0.05). **b**, FACS analyses of Thy1⁺ dsRed⁺ cells from sham-operated or post-MI hearts injected with dsRed-expressing retrovirus, with quantification (left) and representative FACS plots (right) (n=3, *p<0.05). **c**, qPCR analysis of Gata4, Mef2c and Tbx5 in Thy1⁺ dsRed⁺ cells or endogenous cardiomyocytes (CMs) compared to Thy1⁺ dsRed⁻ cells sorted two days after post-MI intramyocardial GMTR (Gata4, Mef2c, Tbx5, and dsRed) injection. n=3 with technical quadruplicates. **d**, Schematic diagram showing the genetic fate mapping method to trace the lineage of CMs reprogrammed from Periostin-Cre:R26R-lacZ or Fsp1-Cre:R26R-lacZ cells. **e**, Immunofluorescent staining for α-Actinin (green), βGalactosidase (βGal, red) and DAPI (blue) on sham-operated or post-MI Periostin-Cre:R26R-lacZ mouse hearts 4 weeks post-surgery. Images are from distant or border zones where endogenous CMs were labeled by α-Actinin, but were never co-localized with βGal (n=5 hearts/condition, 8 sections/heart). Scale bar, 50 μm. **f–g**, Immunofluorescent staining for α-Actinin, βGal and DAPI in infarct areas of dsRed- or GMT-injected Periostin-Cre:R26R-lacZ (**f**) or Fsp1-Cre:R26R-lacZ (**g**) mouse hearts 4 weeks post-MI. Boxed areas indicate regions of magnification. Scale bar, 50 μm. Error bars indicate standard error of the mean (SEM).




Figure 2. Cellular analysis of the degree of *in vivo* cardiac reprogramming

a, Immunofluorescent (IF) staining for YFP, dsRed, and DAPI on heart sections from tamoxifen “pulse-labeled” reprogrammed hearts injected with GMT plus dsRed (GMTR). Scale bar, 50 μ m. **b**, IF staining for YFP, dsRed, and DAPI on isolated CMs from the infarct/border zone of pulse-labeled reprogrammed hearts. Scale bar: 100 μ m. **c**, Quantification of the percentage of YFP⁺ cardiomyocytes in the infarct/border zone of pulse-labeled mouse hearts injected with dsRed (control) or GMT compared to sham (***p*<0.01, *n*=3). **d–f**, IF staining for β Gal and DAPI on isolated CMs from the infarct/border zone of Postn-Cre:R26R-lacZ hearts 4 weeks after dsRed (**d**) or GMT (**e**) injection with quantification in (**f**). *n*=221 cells from three hearts for dsRed group; *n*=182 cells from three hearts for GMT group. Scale bar, 200 μ m. **g–k**, Bright-field image of CMs isolated from GMTR-injected Postn-Cre:R26R-lacZ hearts 4 weeks after MI (**g**). Among these cells, a β Gal positive cell is shown (**h**) that also co-stained with dsRed (**j,k**). Scale bar, 50 μ m. **l–o**, Immunofluorescent staining for cardiac markers—including α -Actinin, Tropomyosin, cardiac myosin heavy chain (MHC), and cardiac Troponin T (cTnT)—co-labeled with β Gal and DAPI, in isolated CMs from the infarct/border zone of Postn-Cre:R26R-lacZ hearts 4 weeks after GMT injection. The images display representative reprogrammed CMs next to endogenous CMs from the same preparation. Quantification of cells with full sarcomere

development is shown, with the full spectrum of marker expression, localization, and quantification shown in Suppl. Fig. 8. White boxes in the merged pictures indicate the areas for high magnification images shown in the far right panels. Scale bar, 50 μm for the first three columns, 20 μm for the last column. **p–q**, Electron microscopy of endogenous CMs or reprogrammed CMs, as identified by the Postn-Cre:R26R-Tomato lineage marker (Tomato⁺ CM). Asterisk indicates mitochondria and brackets indicate sarcomeric units. Scale bar, 2 μm . **r**, Heat map of gene expression for a panel of CM- or fibroblast-enriched genes in isolated adult cardiac fibroblasts (CFs), CMs or iCMs based on lineage markers. The complete data set with statistics is provided in Suppl. Fig. 9. Error bars indicate standard error of the mean (SEM).




Figure 3. Electrophysiological properties of induced cardiomyocytes
a–b, Immunofluorescent staining for N-Cadherin (**a**) or Connexin 43 (**b**), co-labeled with β Gal and DAPI in isolated CMs from Postn-Cre:R26R-lacZ hearts 4 weeks after injury. Boxed areas are shown in higher magnification with the percent of cells having the indicated morphology. Green cells represent endogenous CMs, and red/orange cells are iCMs. (**c**) Immunohistochemistry for Connexin 43 on sections from the infarct/border zone of Postn-Cre:R26R-lacZ hearts 4 weeks after GMT injection. Scale bar: 50 μ m in the 1st and 3rd columns of (**a,b**) and all of (**c**); 20 μ m in the 2nd and 4th columns of (**a,b**). **d**, Representative images of two CMs in contact with one another, including an iCM (red, cell #1) and an endogenous CM (non-red, cell #2) loaded with large (dextran) or small (calcein) dye. The large blue dextran dye loaded in the iCM (cell #1) by whole-cell patch-clamp method did not travel to the CM (cell #2), but the smaller, gap junction-permeable dye calcein did cross the cell border (n=5). Scale bar: 50 μ m. **e**, Video frames captured from a group of myocytes, including endogenous CMs (non-red, #1&3) and an iCM (red, #2) imaged for Fluo-4 fluorescence transients corresponding to sarcoplasmic reticulum Ca^{2+} releases. Video frames 100 ms apart show that the Ca^{2+} release has spread throughout the myocyte group, including the iCM (n=6). Scale bar: 50 μ m. **f**, Intracellular electrical recording of *in vivo*-derived YFP⁺ iCMs and endogenous YFP⁻ CMs from the same preparation. **g**, Table of

action potential parameters measured for CMs and iCMs, including maximum upstroke velocity (dV/dt_{Max}) and minimum diastolic potential (MDP) measured immediately preceding stimulation, overshoot potential (OSP), and the action potential durations (APD) at 90, 70, and 50% repolarization. **h**, Characteristic single field-stimulated $[Ca^{2+}]$ transients recorded from endogenous (left panel) or induced (right panel) CMs. Lower panels show the simultaneously recorded percent cell shortening responses triggered by the Ca^{2+} transients, in the same two cells. Quantifications from 6 iCMs and 4 endogenous CMs are shown in the right four panels. For experiments performed in **d–h**, Cells were isolated from Postn-Cre:Rosa-YFP mice 8 weeks post-MI and virus transduction. Error bars indicate standard error of the mean (SEM).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 4. *In vivo* delivery of cardiac reprogramming factors improves cardiac function after myocardial infarction

a, Ejection fraction (EF), stroke volume (SV), and cardiac output (CO) of the left ventricle were quantified by magnetic resonance imaging (MRI) 12 weeks after MI (n=9 for each group, *p<0.05). Left four panels show representative transverse images of the thorax, containing hearts at the end of diastole (relaxation) or systole (contraction) from dsRed- or GMT-injected mice, compared to sham-operated age- and strain-matched controls. **b**, qPCR of atrial natriuretic factor (ANF), brain natriuretic peptide (BNP) and Tenascin (TnC) on RNA extracted from the border zone of hearts 4 weeks after MI and injection of dsRed or GMT. **c**, qPCR of collagen type I alpha 1 (Col1a1), Col1a2, Col3a1 and elastin (Eln) on RNA extracted from the border zone of hearts 4 weeks after MI and injection of dsRed or GMT. Data in **(b)** and **(c)** are relative to dsRed-injected sham-operated mice, indicated by the dashed line. n=3 for each genotype with technical quadruplicates. *p<0.05. **d**, Masson-Trichrome staining on heart sections 8 weeks post-MI injected with dsRed or GMT with quantification of scar size. Scale bars: 500 μ m. (dsRed, n=8; GMT, n=9; *p<0.05). **e**, Masson-Trichrome (left panel) and immunofluorescent staining for α -Actinin and/or β Gal (right panels) in GMT injected Postn-Cre:R26R-lacZ mouse heart 4 weeks post-surgery. Scale bars: 500 μ m in the left panel, 50 μ m in the right two panels. Error bars indicate standard error of the mean (SEM).